Many new drugs did not have comparative effectiveness information available at time of FDA approval

Only about half of new drugs approved in the last decade had comparative effectiveness data available at the time of their approval by the U.S. Food and Drug Administration, and approximately two-thirds of new drugs had this information available when alternative treatment options existed, according to a study in the May 4 issue of JAMA.

Read the whole article on Physorg

More from Physorg